22nd Century Group Inc  

(Public, NYSEAMERICAN:XXII)   Watch this stock  
Find more results for XXII
+0.01 (0.30%)
Real-time:   2:24PM EST
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 3.29 - 3.49
52 week 0.85 - 3.55
Open 3.40
Vol / Avg. 3.19M/3.50M
Mkt cap 413.94M
P/E     -
Div/yield     -
EPS -0.13
Shares 123.56M
Beta 3.03
Inst. own 21%
Mar 6, 2018
Q4 2017 22nd Century Group Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 10, 2017
Q3 2017 22nd Century Group Inc Earnings Call
Nov 9, 2017
Q3 2017 22nd Century Group Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -73.20% -94.31%
Operating margin -72.26% -92.74%
EBITD margin - -85.88%
Return on average assets -43.77% -50.34%
Return on average equity -50.30% -64.23%
Employees 46 -
CDP Score - -


9530 Main St
CLARENCE, NY 14031-1915
United States - Map
+1-716-2701523 (Phone)
+1-716-8773064 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Officers and directors

Henry Sicignano III President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
John T. Brodfuehrer Chief Financial Officer, Treasurer
Age: 58
Bio & Compensation  - Reuters
Thomas L. James Esq. Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Paul Rushton Ph.D. Vice President - Plant Biotechnology
Age: 53
Bio & Compensation  - Reuters
Michael R. Moynihan Ph.D. Vice President - Research & Development
Age: 63
Bio & Compensation  - Reuters
James W. Cornell Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Nora B. Sullivan Director
Age: 58
Bio & Compensation  - Reuters
Joseph Alexander Dunn Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Richard M. Sanders Independent Director
Age: 62
Bio & Compensation  - Reuters